Skip to main content

Table 2 Number of biopsied IPF-patients in the clinical trials conducted during the past decade

From: The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis

Study

Number of patients

Number (n)/% of biopsied patients

Pirfenidone

107

- pirfenidone: n = 15/21%

Azuma et al., AJRCCM 2005

- placebo: n = 8/23%

Pirfenidone

267

- high dose: n = 26/24%

Taniguchi et al., Eur Respir J 2010

- low dose: n = 16/29%

- placebo: n = 28/27%

Pirfenidone

CAPACITY I

CAPACITY I

Noble et al., Lancet 2011

435

- 1197 mg: n = 32/37%

CAPACITY I

CAPACITY II

- 2403 mg: n = 86/49%

CAPACITY II

334

- placebo: n = 85/49% CAPACITY II

- pirfenidone: n = 94/55%

- placebo: n = 94/54%

Triple-therapy

155

- triple therapy: n = 38/48%

Demedts et al., NEJM 2005

- control: n = 35/47%

IFIGENIA

- excluded patients: n =24/89%

Interferon gamma-1b

330

- IFN-γ-1b: 62%

Raghu et al., NEJM 2004

- placebo: 67%

Interferon gamma-1b

826

- IFN-γ-1b: n = 305/55%

King et al.,

- placebo n = 151/55%

Lancet 2009

INSPIRE

Bosentan

158

- bosentan: 68%

King et al.,

- placebo: 60%

AJRCCM 2008

BUILD-1

Imatinib

119

- imatinib: n = 25/42%

Daniels et al.,

- placebo: n = 29/48%

AJRCCM 2010

Etanercept

88

- etanercept: n = 28/46%

Raghu et al.,

- placebo: n = 23/41%

AJRCCM 2008

Triple-kinase

432

- placebo: n = 19/22%

Richeldi et al.,

 

- 50 mg × 1: n = 25/29%

NEJM 2011

 

- 50 mg × 2: n = 27/31%

  

- 100 mg × 2: n = 20/23%

  

- 150 mg × 2: n = 29/34%